Savolitinib|Volitinib|HMPL-504; AZD-6094

Savolitinib|Volitinib|HMPL-504; AZD-6094

Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.

Product name: Volitinib(Savolitinib)|Purity>98%| CAS: 1313725-88-0|Molecule Formular: C17H15N9|MW: 345.36|Other Namess: Volitinib; HMPL504; AZD-6094,Volitinib; HMPL-504; AZD6094; HMPL 504; AZD 6094

Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
Volitinib demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.

For research only, not for human use.